Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2021 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Appoints Yuan Xu to its Board of Directors

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
August 02, 2021 16:50 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate Three Dosing Regimens...
July 16, 2021 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
July 15, 2021 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
June 15, 2021 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
June 04, 2021 07:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell...
May 25, 2021 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
May 13, 2021 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia

4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study...
May 05, 2021 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress

IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021 Phase 1 Data from FT516 and FT538 Programs in Relapsed / Refractory Acute Myeloid Leukemia to be Featured...
April 29, 2021 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...